Last edition
News about "Bayer"
WHO and Bayer Renew Partnership to Combat NTDs
The World Health Organization (WHO) and Bayer AG have renewed their partnership to combat Chagas disease, sleeping sickness, and taeniasis, with Bayer pledging USD 9.45 million to support WHO’s efforts through 2030.
Bayer | 06/11/2025 | By Dineshwori
Bayer and Kumquat Biosciences have begun a Phase-I trial of their KRAS G12D inhibitor targeting KRAS-mutated tumors, further bolstering Bayer’s precision oncology pipeline across pancreatic, colorectal, and lung cancers.
Bayer | 11/10/2025 | By Dineshwori | 262
The first participant has been dosed in the pivotal Phase III exPDite-2 trial of bemdaneprocel, an investigational cell therapy, while the first European participants have been enrolled in REGENERATE-PD, a Phase II trial of the gene therapy AB-1005.
Bayer | 23/09/2025 | By Darshana | 109
Tata Elxsi Opens Global Radiology Tech Hub for Bayer
The centre will serve as a global innovation hub, combining Tata Elxsi’s engineering expertise with India’s healthcare ecosystem to accelerate Bayer’s radiology solutions across key markets, including the US and EU.
Bayer | 12/09/2025 | By Dineshwori
Bayer Launches Bayer Co.Lab AdVenture Platform in China
Bayer launches Co.Lab AdVenture to connect biotech startups with global VCs, accelerating early-stage innovation through its lifesciences incubator network.
Bayer | 11/09/2025 | By Dineshwori
Bayer Expands Global Life Sciences Incubator With Launch Of Co.Lab AdVenture
Bayer has launched Co.Lab AdVenture, a new platform under its global life sciences incubator network, designed to connect high-potential biotech start-ups with leading venture capital partners worldwide.
Bayer | 09/09/2025 | By Darshana | 163
US FDA Accepts Gadoquatrane for Review: Bayer
Bayer has submitted New Drug Application (NDA) for low dose contrast agent gadoquatrane to seek approval for contrast-enhanced Magnetic Resonance Imaging (MRI) of the Central Nervous System (CNS) and other body regions for adults and paediatric patients including neonates.
Bayer | 27/08/2025 | By Dineshwori
Alvotech and Advanz Pharma Secure European Approval for Eylea Biosimilar Mynzepli
Alvotech and its commercial partner Advanz Pharma have announced that the European Commission has granted marketing authorisation for Mynzepli (aflibercept), a biosimilar to Eylea, available in both pre-filled syringes and vials.
Bayer | 22/08/2025 | By Dineshwori | 126
Bayer Seeks US FDA Approval of gadoquatrane for MRI of CNS and Other Body Parts
Bayer has submitted a New Drug Application to the US FDA for gadoquatrane, an investigational MRI contrast agent. If approved, it would offer the lowest gadolinium dose among macrocyclic GBCAs in the US, cutting exposure by 60 percent while maintaining diagnostic efficacy.
Bayer | 18/06/2025 | By Abha | 135
Bayer and Evotec to Upgrade Precision Cardiology
Bayer and Evotec have updated the focus of their strategic collaboration to developing innovative precision treatments for cardiovascular diseases (CVDs).
Bayer | 01/05/2024 | By Aishwarya | 356
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy